NCT06739395 Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
| NCT ID | NCT06739395 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Tianjin Medical University Second Hospital |
| Condition | Solid Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 300 participants in total. It began in 2024-11-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main purpose of this study is to explore the feasibility of selecting treatment plans based on genomic variations guided by MTB in patients with advanced refractory solid tumors.
Eligibility Criteria
Inclusion Criteria: 1. Recurrent or metastatic malignant solid tumors diagnosed by histology or cytology; 2. ECOG score 0-4 (3-4 points only for patients with tumor burden); 3. Those who fail or cannot tolerate standard treatment, or those who refuse standard treatment; 4. At least one measurable lesion that meets the RECIST 1.1 standard; 5. Expected survival period ≥ 3 months; 6. Age ≥ 18 years old; 7. Tumor tissue blocks with sufficient formalin fixed paraffin embedding (FFPE), or chest or ascites with cancer cells detected during treatment (not less than 200ml), or excised metastatic lymph nodes, or peripheral blood (approximately 5m1) can be used for genetic testing; 8. Understand and voluntarily participate in this study, and sign the informed consent form. Exclusion Criteria: 1. Patients who have actively undergone or are currently participating in clinical trials for treatment; 2. Serious or uncontrolled medical diseases (i.e. uncontrolled diabetes, chronic kidney disease, chronic lung disease or uncontrolled active infection, mental diseases/social conditions that limit the compliance with the research requirements) that the researchers think will confuse the research treatment response analysis; 3. Pregnant or lactating patients, or any patients with fertility, have not taken appropriate pregnancy prevention measures.
Contact & Investigator
Haitao Wang, Ph.D
PRINCIPAL INVESTIGATOR
Tianjin Medical University Second Hospital
Frequently Asked Questions
Who can join the NCT06739395 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Solid Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06739395 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06739395 currently recruiting?
Yes, NCT06739395 is actively recruiting participants. Contact the research team at peterrock2000@126.com for enrollment information.
Where is the NCT06739395 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT06739395 clinical trial?
NCT06739395 is sponsored by Tianjin Medical University Second Hospital. The principal investigator is Haitao Wang, Ph.D at Tianjin Medical University Second Hospital. The trial plans to enroll 300 participants.